Certara, Inc. Overview
Pro stress-test →Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development, serving more than 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries. Regulatory shifts and long-term outsourcing trends are boosting demand for Certara's biosimulation and data-driven modeling solutions, supporting recurring revenue growth and market expansion.
Strategic Profile
Pro stress-test →Product innovation, strategic acquisitions, and cloud-based SaaS models increase customer retention, cross-selling, and margins, enhancing long-term profitability and earnings stability. The company completed the Chemaxon acquisition and launched new products, while repurchasing $41M in stock and repricing a term loan.
Competitive Landscape
Pro stress-test →Competitors in the broader biosimulation and healthcare software space include Simulations Plus, Inc., Schrödinger, Inc., and Definitive Healthcare Corp. Certara maintains a unique position as the leading dedicated biosimulation platform provider serving pharma's model-informed drug development processes.
Industry Context
Certara, Inc. operates in Pharmaceutical Software & Biosimulation Services.
Key facts
Founded: Unknown · Headquarters: Unknown, US · Employees: Unknown · Revenue: $415-420M (2025 guidance) · Market cap: $1.05B